• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Surgical resection of localized hepatocellular carcinoma: patient selection and special consideration.局限性肝细胞癌的手术切除:患者选择及特殊考量
J Hepatocell Carcinoma. 2016 Dec 28;4:1-9. doi: 10.2147/JHC.S96085. eCollection 2017.
2
Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.经动脉放射性栓塞联合化疗栓塞治疗双叶肝细胞癌的安全性和有效性:一项单中心回顾性研究
Cardiovasc Intervent Radiol. 2018 Mar;41(3):459-465. doi: 10.1007/s00270-017-1826-7. Epub 2017 Oct 24.
3
Transarterial Chemoembolization and (90)Y Radioembolization for Hepatocellular Carcinoma: Review of Current Applications Beyond Intermediate-Stage Disease.经动脉化疗栓塞术和(90)钇放射性栓塞术治疗肝细胞癌:超越中期疾病的当前应用综述。
AJR Am J Roentgenol. 2015 Oct;205(4):742-52. doi: 10.2214/AJR.15.14802.
4
Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.肝细胞癌经动脉化疗栓塞与经动脉放射性栓塞治疗:治疗方式选择的优化
Hepatol Int. 2016 Nov;10(6):883-892. doi: 10.1007/s12072-016-9722-9. Epub 2016 Apr 28.
5
Preoperative portal vein embolization and surgical resection in patients with hepatocellular carcinoma and small future liver remnant volume: comparison with transarterial chemoembolization.肝细胞癌且未来肝残余体积小的患者的术前门静脉栓塞和手术切除:与经动脉化疗栓塞的比较
Ann Surg Oncol. 2007 Dec;14(12):3501-9. doi: 10.1245/s10434-007-9553-y. Epub 2007 Sep 25.
6
Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein.除索拉非尼外用于侵袭门静脉的晚期肝细胞癌患者的有效治疗策略。
World J Hepatol. 2015 Jun 18;7(11):1553-61. doi: 10.4254/wjh.v7.i11.1553.
7
Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion: a prospective comparative study.术前化疗栓塞术治疗可切除的伴门静脉侵犯肝细胞癌的疗效与安全性:一项前瞻性对照研究
Eur Radiol. 2016 Jul;26(7):2078-88. doi: 10.1007/s00330-015-4021-8. Epub 2015 Sep 22.
8
Prognostic effect of preoperative sequential transcatheter arterial chemoembolization and portal vein embolization for right hepatectomy in patients with solitary hepatocellular carcinoma.术前序贯经导管动脉化疗栓塞和门静脉栓塞对孤立性肝细胞癌患者右半肝切除术的预后影响
Korean J Hepatobiliary Pancreat Surg. 2015 May;19(2):59-65. doi: 10.14701/kjhbps.2015.19.2.59. Epub 2015 May 31.
9
[Application of portal vein chemoembolization in major hepatectomy for initially unresectable primary and secondary hepatic tumors].门静脉化疗栓塞在初始不可切除的原发性和继发性肝肿瘤大肝切除术中的应用
Zhonghua Yi Xue Za Zhi. 2011 Mar 1;91(8):532-4.
10
Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.对于经动脉化疗栓塞后降期的初始不可切除肝细胞癌患者,挽救性肝切除是否必要?十年经验。
Oncologist. 2016 Dec;21(12):1442-1449. doi: 10.1634/theoncologist.2016-0094. Epub 2016 Aug 2.

引用本文的文献

1
Tenofovir disoproxil fumarate versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma after surgical resection: a systematic review and meta-analysis.替诺福韦酯与恩替卡韦对乙型肝炎病毒相关肝细胞癌手术切除后预后的影响:一项系统评价和荟萃分析
Front Oncol. 2025 May 27;15:1462794. doi: 10.3389/fonc.2025.1462794. eCollection 2025.
2
Bioinformatics analysis of immune infiltrates and tripartite motif () family genes in hepatocellular carcinoma.肝细胞癌中免疫浸润与三联基序(TRIM)家族基因的生物信息学分析
J Gastrointest Oncol. 2022 Aug;13(4):1942-1958. doi: 10.21037/jgo-22-619.
3
Long-Term Survival Impact of High-Grade Complications after Liver Resection for Hepatocellular Carcinoma: A Retrospective Single-Centre Cohort Study.肝癌切除术后高级别并发症对长期生存的影响:一项回顾性单中心队列研究。
Medicina (Kaunas). 2022 Apr 12;58(4):534. doi: 10.3390/medicina58040534.
4
CK-3, A Novel Methsulfonyl Pyridine Derivative, Suppresses Hepatocellular Carcinoma Proliferation and Invasion by Blocking the PI3K/AKT/mTOR and MAPK/ERK Pathways.新型甲磺酰基吡啶衍生物CK-3通过阻断PI3K/AKT/mTOR和MAPK/ERK信号通路抑制肝癌细胞的增殖和侵袭。
Front Oncol. 2021 Jul 28;11:717626. doi: 10.3389/fonc.2021.717626. eCollection 2021.
5
(Fedde ex H.Wolff) Pimenov & Kljuykov Extract Suppresses Proliferation of HepG2 Cells via the PTEN-PI3K-AKT Pathway Uncovered by Integrating Network Pharmacology and Experiments.(源自 H. 沃尔夫)皮缅诺夫和克柳伊科夫提取物通过整合网络药理学与实验揭示的 PTEN - PI3K - AKT 通路抑制 HepG2 细胞增殖
Front Pharmacol. 2021 Apr 20;12:620897. doi: 10.3389/fphar.2021.620897. eCollection 2021.
6
Impact of hepatitis C treatment on long-term outcomes for patients with hepatocellular carcinoma: a United States Safety Net Collaborative Study.丙型肝炎治疗对肝细胞癌患者长期结局的影响:美国医疗保障安全网协作研究。
HPB (Oxford). 2021 Mar;23(3):422-433. doi: 10.1016/j.hpb.2020.07.012. Epub 2020 Aug 7.
7
Impact of tenofovir antiviral treatment on survival of chronic hepatitis B related hepatocellular carcinoma after hepatectomy in Chinese individuals from Qingdao municipality.替诺福韦抗病毒治疗对青岛市中国慢性乙型肝炎相关肝细胞癌患者肝切除术后生存的影响
Medicine (Baltimore). 2020 Aug 7;99(32):e21454. doi: 10.1097/MD.0000000000021454.
8
Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors.肝细胞癌中的异质性反应:免疫检查点抑制剂的致命弱点。
Am J Cancer Res. 2020 Apr 1;10(4):1085-1102. eCollection 2020.
9
Clinical features of hepatocellular carcinoma with hepatitis B virus among patients on Nucleos(t) ide analog therapy.接受核苷(酸)类似物治疗的乙肝患者中肝细胞癌的临床特征
Infect Agent Cancer. 2020 Feb 4;15:8. doi: 10.1186/s13027-020-0277-y. eCollection 2020.
10
A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed.癌症可治愈性综述:需要为新型治疗选择付出更多努力。
Cancers (Basel). 2019 Nov 13;11(11):1782. doi: 10.3390/cancers11111782.

本文引用的文献

1
Liver Resection for De Novo Hepatocellular Carcinoma Complicated by Pyogenic Liver Abscess: A Clinical Challenge.肝切除治疗合并化脓性肝脓肿的初发性肝细胞癌:一项临床挑战
World J Surg. 2016 Feb;40(2):412-8. doi: 10.1007/s00268-015-3239-6.
2
Proposal of the performance status combined Japan Integrated Staging system in hepatocellular carcinoma complicated with cirrhosis.提出联合日本综合分期系统和肝硬化的肝癌功能状态评估标准。
Int J Oncol. 2015;46(6):2371-9. doi: 10.3892/ijo.2015.2969. Epub 2015 Apr 17.
3
Learning curve for laparoscopic major hepatectomy.腹腔镜下肝切除术的学习曲线。
Br J Surg. 2015 Jun;102(7):796-804. doi: 10.1002/bjs.9798. Epub 2015 Apr 15.
4
Anatomical versus non-anatomical resection for hepatocellular carcinoma.解剖性肝切除术与非解剖性肝切除术治疗肝细胞癌的比较。
Br J Surg. 2015 Jun;102(7):776-84. doi: 10.1002/bjs.9815. Epub 2015 Apr 2.
5
Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka.腹腔镜肝切除术推荐意见:在盛冈召开的第二届国际共识会议报告
Ann Surg. 2015 Apr;261(4):619-29. doi: 10.1097/SLA.0000000000001184.
6
Intraoperative simulation of remnant liver function during anatomic liver resection with indocyanine green clearance (LiMON) measurements.在解剖性肝切除术中通过吲哚菁绿清除率(LiMON)测量对残余肝功能进行术中模拟。
HPB (Oxford). 2015 Jun;17(6):471-6. doi: 10.1111/hpb.12380. Epub 2015 Jan 8.
7
Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis.伴有门静脉癌栓的晚期肝细胞癌肝切除术后的生存率
World J Gastroenterol. 2015 Jan 7;21(1):246-53. doi: 10.3748/wjg.v21.i1.246.
8
Outcomes of hepatectomy for hepatocellular carcinoma with bile duct tumour thrombus.肝细胞癌合并胆管癌栓行肝切除的疗效
HPB (Oxford). 2015 May;17(5):401-8. doi: 10.1111/hpb.12368. Epub 2014 Nov 19.
9
Early survival and safety of ALPPS: first report of the International ALPPS Registry.联合肝脏离断和门静脉结扎的二步肝切除术(ALPPS)的早期生存和安全性:国际 ALPPS 注册中心的首次报告。
Ann Surg. 2014 Nov;260(5):829-36; discussion 836-8. doi: 10.1097/SLA.0000000000000947.
10
A novel difficulty scoring system for laparoscopic liver resection.一种用于腹腔镜肝切除术的新型难度评分系统。
J Hepatobiliary Pancreat Sci. 2014 Oct;21(10):745-53. doi: 10.1002/jhbp.166.

局限性肝细胞癌的手术切除:患者选择及特殊考量

Surgical resection of localized hepatocellular carcinoma: patient selection and special consideration.

作者信息

Ma Ka Wing, Cheung Tan To

机构信息

Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Pok Fu Lam, Hong Kong.

出版信息

J Hepatocell Carcinoma. 2016 Dec 28;4:1-9. doi: 10.2147/JHC.S96085. eCollection 2017.

DOI:10.2147/JHC.S96085
PMID:28097107
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5207474/
Abstract

Localized hepatocellular carcinoma (HCC) refers to a solitary or few tumors located within either the left or right hemiliver without evidence of bilobar or extrahepatic spread. This term encompasses a heterogeneous morphology with no regard to stage of prognosis of the disease. Surgical resection remains the mainstay of curative treatment for the localized HCC. Various biochemical and radiological tests constitute an indispensible part of preoperative assessment. Emergence of laparoscopic hepatectomy has brought liver resection into a new era. Improved understanding of the pathophysiology of HCC allows more aggressive surgical resection without compromising outcomes. New insights into the management of special situations, such as ruptured HCC, pyogenic transformation of HCC, and HCC with portal vein tumor thrombus, rekindle the hopes of curative resection in these terminal events. Amalgamating salvage liver transplantation into the surgical management of resectable HCC has revolutionized the treatment paradigm of this deadly disease.

摘要

局限性肝细胞癌(HCC)是指位于肝左叶或右叶内的单个或少数肿瘤,无双侧或肝外扩散的证据。该术语涵盖了异质性形态,而不考虑疾病的预后阶段。手术切除仍然是局限性HCC根治性治疗的主要方法。各种生化和放射学检查是术前评估不可或缺的一部分。腹腔镜肝切除术的出现使肝切除进入了一个新时代。对HCC病理生理学的深入了解使得在不影响预后的情况下能够进行更积极的手术切除。对特殊情况(如破裂性HCC、HCC的化脓性转化和伴有门静脉肿瘤血栓的HCC)管理的新见解,重新点燃了在这些终末期事件中进行根治性切除的希望。将挽救性肝移植纳入可切除HCC的外科治疗中,彻底改变了这种致命疾病的治疗模式。